The report, which levels the same allegations at CVS and Cigna, is the latest indictment of America’s broken healthcare ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...
Witty's comments came during the company's first earnings call since the killing of Brian Thompson, the CEO of the company's ...
Andrew Witty, UnitedHealth CEO, said the move will remove an excuse other players use to blame Optum Rx for high drug costs.
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
(Bloomberg) -- Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average acquisition cost for dozens of specialty generic drugs, bringing ...
Elevance Health's financial outlook for FY 2025 anticipates GAAP diluted earnings per share (EPS) to be in the range of $30.40 to $31.10 and adjusted diluted EPS to be in the range of $34.15 to $34.85 ...